NASDAQ:NVNO

enVVeno Medical Q3 2026 Earnings Results & Report

enVVeno Medical logo
$5.95 -0.22 (-3.57%)
Closing price 04:00 PM Eastern
Extended Trading
$5.91 -0.04 (-0.67%)
As of 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

enVVeno Medical missed analyst earnings expectations in its Q3 2026 results, released October 29, 2026. The company reported EPS of -$6.29 versus the -$3.27 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes

enVVeno Medical EPS Results

Actual EPS
-$6.29
Consensus EPS
-$3.27
Beat/Miss
Missed by -$3.02
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 6 quarters

enVVeno Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.25 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

enVVeno Medical Q3 2026 Earnings FAQ

enVVeno Medical (NASDAQ:NVNO) reported earnings of -$6.29 per share for Q3 2026, missing the consensus estimate of -$3.27. The report was announced on Thursday, October 29, 2026.

enVVeno Medical Earnings Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
See More enVVeno Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enVVeno Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enVVeno Medical and other key companies, straight to your email.

About enVVeno Medical

enVVeno Medical (NASDAQ:NVNO) is a medical-device company developing treatments for chronic venous disease, with a focus on deep venous chronic venous insufficiency. This condition can occur when valves in the leg’s deep veins do not function properly, impairing blood flow back to the heart.

The company’s lead product, VenoValve, is a bioprosthetic valve designed to restore valve function in affected deep veins. enVVeno has also described a transcatheter valve program, enVVe, intended to provide a less invasive approach to treating the condition.

Previously known as Hancock Jaffe Laboratories, the company adopted the enVVeno Medical name in 2021. It is based in Irvine, California, and its development efforts are directed primarily toward the U.S. market.

View enVVeno Medical Profile